Completed NA INTERVENTIONAL 2-arm NCT01217528

Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients (DECREASE)

Reduction of Inappropriate ICD Therapies in Patients With Approved Indication for Primary Prevention of Sudden Cardiac Death

Sponsor: Abbott Medical Devices

Conditions Cardiac Death

Interventions Device settings for group B device settings for group A

Updated 8 times since 2017 Last updated: Feb 1, 2019 Started: Aug 31, 2009 Primary completion: Sep 30, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01217528, this NA trial focuses on Cardiac Death and remains completed. Sponsored by Abbott Medical Devices, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Mar 2019 — Jan 2021 [monthly]

Completed NA

▶ Show 3 earlier versions

Feb 2019 — Mar 2019 [monthly]

Completed NA
Jun 2018 — Feb 2019 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott Medical Devices

Data source: Abbott Medical Devices

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Altenburg, Germany , Attendorn, Germany , Bonn, Germany , Coburg, Germany , Cologne, Germany , Ebermannstadt, Germany , Ebersberg, Germany , Erfurt, Germany , Esslingen am Neckar, Germany and 21 more locations